Inhibikase Therapeutics (IKT) Company Report

Inhibikase Therapeutics, Inc. entered into an underwriting agreement on November 20, 2025, for a public offering of 46,091,739 shares of common stock and 22,873,779 pre-funded warrants.
Each share was offered at $1.45, and each pre-funded warrant at $1.449.
The company estimates net proceeds of approximately $93.6 million, which could increase to $107.7 million if the underwriters fully exercise their option to purchase an additional 10,344,827 shares.
The offering is expected to close on November 24, 2025.
The company also amended the terms of its Series A-1 and Series B-1 Warrants, issued on October 21, 2024, to reflect plans to advance IKT-001 to a global pivotal Phase 3 clinical trial in PAH.

Nov 21, 2025, 9:28 PM

Inhibikase Therapeutics Announces Pricing of Public Offering

IKT

Inhibikase Therapeutics, Inc. (IKT) has announced the pricing of an underwritten public offering expected to generate approximately $100.0 million in aggregate gross proceeds before deductions.
The offering includes 46,091,739 shares of common stock priced at $1.45 per share and 22,873,779 pre-funded warrants at $1.449 per warrant.
The underwriters have been granted a 30-day option to purchase up to an additional 10,344,827 shares of common stock.
The offering is expected to close on November 24, 2025.

Nov 21, 2025, 2:54 AM

Inhibikase Therapeutics to Advance IKT-001 to Phase 3 Study for PAH, Terminates ATM Prospectus

IKT

New Projects/Investments

Guidance Update

Inhibikase Therapeutics, Inc. (IKT) announced on November 20, 2025, its plan to advance IKT-001 into a global pivotal Phase 3 clinical study for Pulmonary Arterial Hypertension (PAH).
The IMPROVE-PAH study, designed as a two-part adaptive Phase 3 trial, is expected to commence in the first quarter of 2026. Part A will enroll 140 patients with a primary endpoint of PVR at Week 24, and Part B will enroll 346 patients with a primary endpoint of 6MWD at Week 24.
Effective November 20, 2025, the company terminated its sales agreement prospectus, halting any further sales of common stock under the existing Sales Agreement unless a new prospectus is filed.

Nov 20, 2025, 9:11 PM

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Clinical Trial Advancement

IKT

Earnings

New Projects/Investments

Management Change

Inhibikase Therapeutics reported a net loss of $11.9 million, or $0.13 per share, for the third quarter ended September 30, 2025. For the nine months ended September 30, 2025, the net loss was $35.5 million, or $0.40 per share.
As of September 30, 2025, cash, cash equivalents, and marketable securities were $77.3 million, a decrease from $97.5 million as of December 31, 2024.
Research and development expenses for the third quarter of 2025 were $7.6 million, and selling, general and administrative expenses were $5.6 million.
The company expects to initiate its Phase 2b IMPROVE-PAH clinical study of IKT-001 for Pulmonary Arterial Hypertension (PAH) during the fourth quarter of 2025.
Timothy Pigot was appointed as the Chief Commercial and Strategy Officer.

Nov 14, 2025, 9:25 PM

Inhibikase Therapeutics Announces Q3 2025 Financial Results and Clinical Trial Plans

IKT

Earnings

New Projects/Investments

Management Change

Inhibikase Therapeutics reported a net loss of $11.9 million, or $0.13 per share, for the quarter ended September 30, 2025.
As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $77.3 million.
The company expects to initiate its Phase 2b clinical study of IKT-001, named IMPROVE-PAH, in Pulmonary Arterial Hypertension (PAH) during the fourth quarter of 2025.
Timothy Pigot was appointed as the Chief Commercial and Strategy Officer.